Evidence map›Paper›PMID 32322110›Full record

ArticleGeburtshilfe und Frauenheilkunde2020

Criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for the Classification of Germline Sequence Variants in Risk Genes for Hereditary Breast and Ovarian Cancer.

Barbara Wappenschmidt, Jan Hauke, Ulrike Faust, Dieter Niederacher, Lisa Wiesmüller, Gunnar Schmidt, Evi Groß, Andrea Gehrig, Christian Sutter, Juliane Ramser and 3 more

Abstract read
In one paragraph

Article in Geburtshilfe und Frauenheilkunde, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Review
  3. Reclassification of VUS inGenetics in medicine open · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. A NovelHuman mutation · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Barbara WappenschmidtZentrum familiärer Brust- und Eierstockkrebs, Universitätsklinikum Köln, Köln, Germany.
Jan HaukeZentrum familiärer Brust- und Eierstockkrebs, Universitätsklinikum Köln, Köln, Germany.
Ulrike FaustInstitut für Medizinische Genetik und Angewandte Genomik, Universität Tübingen, Tübingen, Germany.
Dieter NiederacherKlinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Düsseldorf, Düsseldorf, Germany.
Lisa WiesmüllerFrauenklinik, Sektion Gynäkologische Onkologie, Uniklinik Ulm, Ulm, Germany.
Gunnar SchmidtInstitut für Humangenetik, Medizinische Hochschule Hannover, Hannover, Germany.
Evi GroßKlinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, Campus Großhadern, München, Germany.
Andrea GehrigInstitut für Humangenetik, Universität Würzburg, Würzburg, Germany.
Christian SutterInstitut für Humangenetik, Universität Heidelberg, Heidelberg, Germany.
Juliane RamserFrauenklinik der Technischen Universität München, Klinikum rechts der Isar, München, Germany.
Andreas RumpInstitut für klinische Genetik, Technische Universität Dresden, Dresden, Germany.
Norbert ArnoldUniversitätsklinikum Kiel, Klinik für Gynäkologie und Geburtshilfe, Kiel, Germany.
Alfons MeindlKlinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, Campus Großhadern, München, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

More than ten years ago, the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) set up a panel of experts (VUS Task Force) which was tasked with reviewing the classifications of genetic variants reported by individual centres of the GC-HBOC to the central database in Leipzig and reclassifying them, where necessary, based on the most recent data. When it evaluates variants, the VUS Task Force must arrive at a consensus. The resulting classifications are recorded in a central database where they serve as a basis for ensuring the consistent evaluation of previously known and newly identified variants in the different centres of the GC-HBOC. The standardised VUS evaluation by the VUS Task Force is a key element of the recall system which has also been set up by the GC-HBOC. The system will be used to pass on information to families monitored and managed by GC-HBOC centres in the event that previously classified variants are reclassified based on new information. The evaluation algorithm of the VUS Task Force was compiled using internationally established assessment methods (IARC, ACMG, ENIGMA) and is presented here together with the underlying evaluation criteria used to arrive at the classification decision using a flow chart. In addition, the characteristics and special features of specific individual risk genes associated with breast and/or ovarian cancer are discussed in separate subsections. The URLs of relevant databases have also been included together with extensive literature references to provide additional information and cover the scope and dynamism of the current state of knowledge on the evaluation of genetic variants. In future, if criteria are updated based on new information, the update will be published on the website of the GC-HBOC ( https://www.konsortium-familiaerer-brustkrebs.de/ ).

Indexed as

classification of genetic variantshereditary breast/ovarian cancerrisk genes

Identifiers

PMID32322110
PMCPMC7174002

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.